Literature DB >> 34178832

Association of TNF-α-308 G>A (rs1800629) polymorphism with susceptibility of metabolic syndrome.

Dalia Ghareeb1, Abdallah S Abdelazem2, Ekhlas M Hussein3, Amira S Al-Karamany4.   

Abstract

BACKGROUND: Metabolic Syndrome (MetS) mainly comprises hyperglycemia, hypertension and dyslipidemia, and has been proven to increase the risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease. Studies have suggested that many factors may be involved in the pathogenesis of MetS, but tumor necrosis factor alpha (TNF- α) may play a strong role as its gene polymorphism was associated with insulin resistance and obesity. The aim of this study was to evaluate the possible association of TNF-α-308 G > A (rs1800629) polymorphism with susceptibility of metabolic syndrome.
METHODS: a case-control study was conducted upon 128 participants recruited from Suez Canal University Hospital (Ismailia, Egypt), divided into the MetS group (n = 64) and the control group (n = 64). Genotyping of the TNF-α-308 G > A (rs1800629) polymorphism was performed by restriction fragment length polymorphism (PCR-RFLP).
RESULTS: The A allele was significantly higher among MetS patients (40%) than controls (11%) (p < 0.0001). A significant association was observed between the healthy and MetS groups under the influence of co-dominant, dominant and over-dominant genetic models (p < 0.05). Also, there were positive correlations between TNF-α-308 (G/A) polymorphism and risk factors of metabolic syndrome like body mass index (BMI); fasting blood sugar; cholesterol and low density lipoprotein (LDL) (p < 0.05). Regression analysis was done for predictors of MetS and the A allele was found to be a strong predictor (OR 2.752; 95% CI = 1.106 to 6.847; p = 0.03), as well as, BMI; triglyceride (TG); high density lipoprotein (HDL); LDL and cholesterol (p < 0.05).
CONCLUSIONS: TNF-α-308 G > A (rs1800629) polymorphism may be play an important role in the development of metabolic syndrome and A allele is a strong predictor in Egyptians. © Springer Nature Switzerland AG 2021.

Entities:  

Keywords:  Gene polymorphism; Metabolic syndrome; Polymerase chain reaction; Restriction fragment length polymorphism; Tumor necrosis factor alpha

Year:  2021        PMID: 34178832      PMCID: PMC8212250          DOI: 10.1007/s40200-021-00732-3

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  31 in total

Review 1.  Genetics of metabolic syndrome.

Authors:  Alena Stančáková; Markku Laakso
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

2.  Association of TNF-α promoter gene G-308A polymorphism with metabolic syndrome, insulin resistance, serum TNF-α and leptin levels in Indian adult women.

Authors:  Vani Gupta; Abhishek Gupta; Tabrez Jafar; Vandana Gupta; Suraksha Agrawal; Nidhi Srivastava; Sandeep Kumar; Arun K Singh; S M Natu; C G Agarwal; G G Agarwal
Journal:  Cytokine       Date:  2011-05-26       Impact factor: 3.861

Review 3.  Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome.

Authors:  Silvia C Sookoian; Claudio González; Carlos J Pirola
Journal:  Obes Res       Date:  2005-12

4.  The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity.

Authors:  Tongjian You; Barbara J Nicklas; Jingzhong Ding; Brenda W J H Penninx; Bret H Goodpaster; Douglas C Bauer; Frances A Tylavsky; Tamara B Harris; Stephen B Kritchevsky
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2008-04       Impact factor: 6.053

5.  Segment of rat chromosome 20 regulates diet-induced augmentations in adiposity, glucose intolerance, and blood pressure.

Authors:  Zdenka Pausova; Lucie Sedova; Julie Berube; Pavel Hamet; Johanne Tremblay; Marc Dumont; Daniel Gaudet; Michal Pravenec; Vladimir Kren; Jaroslav Kunes
Journal:  Hypertension       Date:  2003-03-24       Impact factor: 10.190

6.  Structural equation model-based genome scan for the metabolic syndrome.

Authors:  Catherine M Stein; Yeunjoo Song; Robert C Elston; Gyungah Jun; Hemant K Tiwari; Sudha K Iyengar
Journal:  BMC Genet       Date:  2003-12-31       Impact factor: 2.797

Review 7.  A comprehensive review on metabolic syndrome.

Authors:  Jaspinder Kaur
Journal:  Cardiol Res Pract       Date:  2014-03-11       Impact factor: 1.866

Review 8.  Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population.

Authors:  Krithika Srikanthan; Andrew Feyh; Haresh Visweshwar; Joseph I Shapiro; Komal Sodhi
Journal:  Int J Med Sci       Date:  2016-01-01       Impact factor: 3.738

9.  Serum profile of cytokines and their genetic variants in metabolic syndrome and healthy subjects: a comparative study.

Authors:  Uzma Zafar; Saba Khaliq; Hafiz Usman Ahmad; Khalid Pervaiz Lone
Journal:  Biosci Rep       Date:  2019-02-01       Impact factor: 3.840

10.  An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles.

Authors:  A G Wilson; N de Vries; F Pociot; F S di Giovine; L B van der Putte; G W Duff
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  2 in total

1.  Development of a genetic risk score for obesity predisposition evaluation.

Authors:  Armin Soleymaniniya; Sobhan Bahrami Zadegan; Narges Damavandi; Mohammad Hasan Samiee Aref; Sirous Zeinali
Journal:  Mol Genet Genomics       Date:  2022-08-10       Impact factor: 2.980

2.  The Association between Single Nucleotide Polymorphisms, including miR-499a Genetic Variants, and Dyslipidemia in Subjects Treated with Pharmacological or Phytochemical Lipid-Lowering Agents.

Authors:  Angelica Giuliani; Alberto Montesanto; Giulia Matacchione; Laura Graciotti; Deborah Ramini; Olga Protic; Roberta Galeazzi; Roberto Antonicelli; Elena Tortato; Anna Rita Bonfigli; Jacopo Sabbatinelli; Fabiola Olivieri
Journal:  Int J Mol Sci       Date:  2022-05-17       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.